文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局部晚期宫颈癌放化疗后近距离放疗对治疗前18F-FDG PET/CT高摄取区剂量覆盖不足对结局的影响

Impact of suboptimal dosimetric coverage of pretherapeutic 18F-FDG PET/CT hotspots on outcome in patients with locally advanced cervical cancer treated with chemoradiotherapy followed by brachytherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-05-11

本研究匹配42例局部晚期宫颈癌放化疗后复发患者与42例未复发患者,分析近距离放疗对治疗前18F-FDG PET/CT高摄取区(热点)的剂量覆盖。复发组41%患者热点未被高危临床靶区包含且未被85 Gy等剂量线覆盖,未复发组仅7%,热点85 Gy覆盖在未复发患者中显著更优但仅与远处复发患者比较有统计学意义。

要点

  • 复发组41%患者PET热点未被高危临床靶区包含且未被85 Gy等剂量线覆盖,未复发组仅7%。
  • 热点85 Gy覆盖在未复发患者中显著更优,但仅与远处复发患者比较有统计学意义(p<0.0001)。
  • 治疗前PET高摄取区剂量覆盖不足可能与复发风险增加相关。

核心结论

  • 治疗前PET高摄取区的剂量覆盖不足可能与复发风险增加相关。

研究设计与样本

  • 匹配病例对照研究,42例局部晚期宫颈癌放化疗后复发患者与42例未复发患者匹配。
  • 将治疗前PET/CT的CT与放疗计划CT刚性配准,必要时手动平移和形变校正。
  • 应用FLAB算法在PET图像上同时定义整体肿瘤体积和高摄取亚体积V1。
  • 评估V1是否包含在高危临床靶区(CTV HR)内及其剂量覆盖,报告3-4次近距离放疗的平均值。
  • 平均随访26±11个月(均值±标准差)。

主要发现

  • 复发组17/42例(41%)V1未被包含在CTV HR且未被85 Gy等剂量线覆盖(盆腔复发1/20,远处复发16/22)。
  • 复发组7/42例(17%)V1未被80 Gy等剂量线覆盖,均为远处复发。
  • 未复发组仅3例(7%)V1未被包含在CTV HR且未被85 Gy等剂量线覆盖。
  • 热点85 Gy覆盖在未复发患者中显著更好,但仅与远处复发患者比较有统计学意义(p<0.0001)。

关键数值与推荐

  • V1未被包含在CTV HR且未被85 Gy等剂量线覆盖:复发组41%(17/42),未复发组7%(3/42)。
  • V1未被80 Gy等剂量线覆盖:复发组17%(7/42),均为远处复发。
  • 热点85 Gy覆盖比较:未复发 vs 远处复发,p<0.0001。

临床怎么用

  • 对局部晚期宫颈癌患者,近距离放疗计划时应评估治疗前PET/CT高摄取区是否被CTV HR包含及85 Gy等剂量线覆盖。
  • 若高摄取区未被包含或覆盖不足,可考虑优化靶区勾画或剂量分布以改善覆盖。

局限性

  • 样本量较小(42对匹配患者),随访时间有限(平均26±11个月)。
  • 热点85 Gy覆盖的显著差异仅在与远处复发患者比较时成立。
  • 回顾性匹配设计可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Areas of high uptake on pre-treatment 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), denoted as "hotspots", have been identified as preferential sites of local relapse in locally advanced cervical cancer (LACC). The purpose of this study was to analyze the dosimetric coverage of these hotspots with high dose-rate brachytherapy (BT). METHODS: For each patient, a rigid registration of the CT from the pre-treatment PET/CT with the radiotherapy planning CT was performed using 3D SlicerTM, followed by a manual volume correction by translation and deformation if necessary. The fuzzy locally adaptive Bayesian (FLAB) algorithm was applied to PET images to simultaneously define an overall tumour volume and the high-uptake sub-volume V1. The inclusion of V1 in the high-risk clinical target volume (CTV HR) and its dosimetric coverage were evaluated using 3D SlicerTM. The average of the 3-4 BT sessions was reported. RESULTS: Forty-two patients with recurrence after chemoradiotherapy (CRT) for LACC were matched to 42 patients without recurrence. Mean ± standard deviation follow-up was 26 ± 11 months. In the recurrence group, V1 was not included in the CTV HR and not covered by the 85 Gy isodose in 17/42 patients (41%) (1/20 with pelvic recurrence and 16/22 with distant recurrence) and not by the 80 Gy isodose in 7/42 patients (17%) (all with distant recurrence). In the non-recurrence group, V1 was not included in CTV HR and not covered by the 85 Gy isodose in 3 patients only (7%). The hotspots coverage by the 85 Gy isodose was significantly better in patients who did not recur, but only when compared to patients with distant relapse (p < 0.0001). CONCLUSION: Suboptimal dosimetric coverage of high FDG uptakes on pretherapeutic PET could be associated with an increased risk of recurrence.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lucia F, Bourbonne V, Gujral D, et al. Impact of suboptimal dosimetric coverage of pretherapeutic 18F-FDG PET/CT hotspots on outcome in patients with locally advanced cervical cancer treated with chemoradiotherapy followed by brachytherapy. Clin Transl Radiat Oncol. 2020. PMID: 32435702. doi:10.1016/j.ctro.2020.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。